How Biodegradable Polymers Can be Effective Drug Delivery Systems for Cannabinoids? Prospectives and Challenges

References

• Lewis M, Russo E, Smith K. Pharmacological Foundations of Cannabis Chemovars. Planta Med. 2018;84(04):225–233. doi:10.1055/s-0043-122240
   PubMedGoogle Scholar
• Huestis MA. Human Cannabinoid Pharmacokinetics. C&b. 2007;4(8):1770–1804. doi:10.1002/cbdv.200790152
   Google Scholar
• Ward SJ, Lichtman AH, Piomelli D, Parker LA. Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects. JNCI Monogr. 2021;2021(58):78–85. doi:10.1093/jncimonographs/lgab007
   Google Scholar
• Mackie K. Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System. In: Pertwee RG editor. Cannabinoids. Vol 168. Handbook of Experimental Pharmacology. Springer-Verlag; 2005:299–325. doi:10.1007/3-540-26573-2_10
   Google Scholar
• Pertwee RG. Cannabinoid receptors and pain. Progress Neurobiol. 2001;63(5):569–611. doi:10.1016/S0301-0082(00)00031-9
   PubMed Web of Science ®Google Scholar
• Galiegue S, Mary S, Marchand J, et al. Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. Eur J Biochem. 1995;232(1):54–61. doi:10.1111/j.1432-1033.1995.tb20780.x
   PubMedGoogle Scholar
• Ofek O, Karsak M, Leclerc N, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006;103(3):696–701. doi:10.1073/pnas.0504187103
   PubMed Web of Science ®Google Scholar
• Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for Cancer Treatment: progress and Promise. Cancer Res. 2008;68(2):339–342. doi:10.1158/0008-5472.CAN-07-2785
   PubMed Web of Science ®Google Scholar
• Fernández Ó. THC:CBD in Daily Practice: available Data from UK, Germany and Spain. Eur Neurol. 2016;75(Suppl. 1):1–3. doi:10.1159/000444234
   PubMedGoogle Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: a Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456. doi:10.1001/jama.2015.6358
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Internal Med. 2018;49:12–19. doi:10.1016/j.ejim.2018.01.004
   PubMed Web of Science ®Google Scholar
• Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: therapeutic Use in Clinical Practice. IJMS. 2022;23(6):3344. doi:10.3390/ijms23063344
   Google Scholar
• O’Sullivan SE, Jensen SS, Kolli AR, Nikolajsen GN, Bruun HZ, Hoeng J. Strategies to Improve Cannabidiol Bioavailability and Drug Delivery. Pharmaceuticals. 2024;17(2):244. doi:10.3390/ph17020244
   Web of Science ®Google Scholar
• Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3–4):131–149. doi:10.1159/000521683
   PubMed Web of Science ®Google Scholar
• Grymel M, Grabiec P, Nurkowska K. Cannabidiol - characteristic and application in cosmetology and dermatology. Aesth Cosmetol Med. 2021;10(6):299–303. doi:10.52336/acm.2021.10.6.06
   Google Scholar
• Fairbairn JW, Liebmann JA, Rowan MG. The stability of cannabis and its preparations on storage. J Pharm Pharmacol. 2011;28(1):1–7. doi:10.1111/j.2042-7158.1976.tb04014.x
   Google Scholar
• Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S. Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2018;56(4):94–96. doi:10.1515/cclm-2017-0758
   PubMed Web of Science ®Google Scholar
• van Drooge DJ, Hinrichs WLJ, Wegman KAM, Visser MR, Eissens AC, Frijlink HW. Solid dispersions based on inulin for the stabilisation and formulation of Δ9-tetrahydrocannabinol. Eur. J. Pharm. Sci. 2004;21(4):511–518. doi:10.1016/j.ejps.2003.11.014
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Izgelov D, Domb AJ, Hoffman A. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur. J. Pharm. Sci. 2017;109:21–30. doi:10.1016/j.ejps.2017.07.003
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 2017;266:1–7. doi:10.1016/j.jconrel.2017.09.011
   PubMed Web of Science ®Google Scholar
• Stella B, Baratta F, Della Pepa C, Arpicco S, Gastaldi D, Dosio F. Cannabinoid Formulations and Delivery Systems: current and Future Options to Treat Pain. Drugs. 2021;81(13):1513–1557. doi:10.1007/s40265-021-01579-x
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clin. Pharmacokinet. 2003;42(4):327–360. doi:10.2165/00003088-200342040-00003
   PubMed Web of Science ®Google Scholar
• Bonhomme-Faivre L, Benyamina A, Reynaud M, Farinotti R, Abbara C. Disposition of Δ 9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict. Biol. 2008;13(3–4):295–300. doi:10.1111/j.1369-1600.2008.00096.x
   PubMed Web of Science ®Google Scholar
• Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018;9:1365. doi:10.3389/fphar.2018.01365
   PubMed Web of Science ®Google Scholar
• Nelson KM, Bisson J, Singh G, et al. The Essential Medicinal Chemistry of Cannabidiol (CBD). J Med Chem. 2020;63(21):12137–12155. doi:10.1021/acs.jmedchem.0c00724
   PubMed Web of Science ®Google Scholar
• Reddy TS, Zomer R, Mantri N. Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. Phytother Res. 2023;37(4):1526–1538. doi:10.1002/ptr.7742
   PubMed Web of Science ®Google Scholar
• Maurya N, Velmurugan BK. Therapeutic applications of cannabinoids. Chem. Biol. Interact. 2018;293:77–88. doi:10.1016/j.cbi.2018.07.018
   PubMed Web of Science ®Google Scholar
• Phadke A, Amin P. A Recent Update on Drug Delivery Systems for Pain Management. J Pain Palliative Care Pharmacother. 2021;35(3):175–214. doi:10.1080/15360288.2021.1925386
   PubMed Web of Science ®Google Scholar
• Mercadante S. Cancer Pain Treatment Strategies in Patients with Cancer. Drugs. 2022;82(13):1357–1366. doi:10.1007/s40265-022-01780-6
   PubMed Web of Science ®Google Scholar
• Al Malyan M, Becchi C, Nikkola L, et al. Polymer-Based Biodegradable Drug Delivery Systems in Pain Management. J Craniofacial Surgery. 2006;17(2):302–313. doi:10.1097/00001665-200603000-00018
   PubMed Web of Science ®Google Scholar
• Anekar AA, Hendrix JM, Cascella M. WHO Analgesic Ladder. StatPearls Publishing; 2023.
   Google Scholar
• Yang J, Bauer BA, Wahner-Roedler DL, Chon TY, Xiao L. The Modified WHO Analgesic Ladder: is It Appropriate for Chronic Non-Cancer Pain? JPR. 2020;13:411–417. doi:10.2147/JPR.S244173
   Google Scholar
• Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging and Disease. 2018;9(1):143. doi:10.14336/AD.2017.0306
   PubMed Web of Science ®Google Scholar
• Mitra R, Jones S. Adjuvant Analgesics in Cancer Pain: a Review. Am J Hosp Palliat Care. 2012;29(1):70–79. doi:10.1177/1049909111413256
   PubMed Web of Science ®Google Scholar
• Lussier D, Huskey AG, Portenoy RK. Adjuvant Analgesics in Cancer Pain Management. oncologist. 2004;9(5):571–591. doi:10.1634/theoncologist.9-5-571
   PubMed Web of Science ®Google Scholar
• Jahromi B, Pirvulescu I, Candido KD, Knezevic NN. Herbal Medicine for Pain Management: efficacy and Drug Interactions. Pharmaceutics. 2021;13(2):251. doi:10.3390/pharmaceutics13020251
   PubMed Web of Science ®Google Scholar
• Nahin R, Barnes P, Stussman B, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report. 2009;30(18):1–14.
   Google Scholar
• Weiner DK, Ernst E. Complementary and Alternative Approaches to the Treatment of Persistent Musculoskeletal Pain. Clin J Pain. 2004;20(4):244–255. doi:10.1097/00002508-200407000-00006
   PubMed Web of Science ®Google Scholar
• Cai Y, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci. 2004;74(17):2157–2184. doi:10.1016/j.lfs.2003.09.047
   PubMed Web of Science ®Google Scholar
• Li SH, Li L, Yang RN, Liang SD. Compounds of traditional Chinese medicine and neuropathic pain. Chinese J Nat Med. 2020;18(1):28–35. doi:10.1016/S1875-5364(20)30002-9
   PubMed Web of Science ®Google Scholar
• Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004;74(11):1317–1324. doi:10.1016/j.lfs.2003.09.038
   PubMed Web of Science ®Google Scholar
• Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice AS. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162(1):5–25. doi:10.1097/j.pain.0000000000002268
   Google Scholar
• Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuro Psychopharmacol Biol Psychiatry. 2012;38(1):4–15. doi:10.1016/j.pnpbp.2012.02.009
   PubMed Web of Science ®Google Scholar
• Meng H, Deshpande A. Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside. BJA Educ. 2020;20(9):305–311. doi:10.1016/j.bjae.2020.05.002
   PubMed Web of Science ®Google Scholar
• Jose A, Thomas L, Baburaj G, Munisamy M, Rao M. Cannabinoids as an alternative option for conventional analgesics in cancer pain management: a pharmacogenomics perspective. Indian J Palliat Care. 2020;26(1):129. doi:10.4103/IJPC.IJPC_155_19
   PubMed Web of Science ®Google Scholar
• Safi K, Sobieraj J, Błaszkiewicz M, Żyła J, Salata B, Dzierżanowski T. Tetrahydrocannabinol and Cannabidiol for Pain Treatment—An Update on the Evidence. Biomedicines. 2024;12(2):307. doi:10.3390/biomedicines12020307
   PubMed Web of Science ®Google Scholar
• Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;2020(7):182. doi:10.1002/14651858.CD012182.pub2
   Google Scholar
• Johal H, Vannabouathong C, Chang Y, Zhu M, Bhandari M. Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? Therapeutic Adv Musculoskeletal. 2020;12. doi:10.1177/1759720X20937968
   Google Scholar
• van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860–869. doi:10.1097/j.pain.0000000000001464
   PubMed Web of Science ®Google Scholar
• Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pain Med. 2020;21(10):2212–2218. doi:10.1093/pm/pnaa303
   PubMed Web of Science ®Google Scholar
• Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932–1954. doi:10.1097/j.pain.0000000000001293
   PubMed Web of Science ®Google Scholar
• Holt A, Nouhravesh N, Strange JE, et al. Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study. Eur Heart J. 2024;45(6):475–484. doi:10.1093/eurheartj/ehad834
   PubMed Web of Science ®Google Scholar
• Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2018;10(4):a033118. doi:10.1101/cshperspect.a033118
   PubMed Web of Science ®Google Scholar
• Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–1590. doi:10.1016/S0140-6736(20)32205-4
   PubMed Web of Science ®Google Scholar
• Martín-Moreno AM, Reigada D, Ramírez BG, et al. Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: relevance to Alzheimer’s Disease. Mol Pharmacol. 2011;79(6):964–973. doi:10.1124/mol.111.071290
   PubMed Web of Science ®Google Scholar
• Franke T, Irwin C, Beindorff N, Bouter Y, Bouter C. Effects of tetrahydrocannabinol treatment on brain metabolism and neuron loss in a mouse model of sporadic Alzheimer’s disease. Nuklearmedizin. 2019;58(2):9. doi:10.1055/s-0039-1683689
   Google Scholar
• Ruthirakuhan MT, Herrmann N, Gallagher D, et al. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer’s disease: study protocol for a cross-over randomized controlled trial. Contemporary Clin Trials Commun. 2019;15:100385. doi:10.1016/j.conctc.2019.100385
   PubMed Web of Science ®Google Scholar
• Ruthirakuhan M, Herrmann N, Andreazza AC, et al. Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: biomarker Analyses From a Clinical Trial With Nabilone for Agitation. J Geriatr Psychiatry Neurol. 2020;33(4):175–184. doi:10.1177/0891988719874118
   PubMed Web of Science ®Google Scholar
• Davie CA. A review of Parkinson’s disease. Br Med Bul. 2008;86(1):109–127. doi:10.1093/bmb/ldn013
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4(1):19. doi:10.1186/s40035-015-0042-0
   PubMed Web of Science ®Google Scholar
• Zuardi A, Crippa J, Hallak J, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23(8):979–983. doi:10.1177/0269881108096519
   PubMed Web of Science ®Google Scholar
• De Faria SM, De Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 2020;34(2):189–196. doi:10.1177/0269881119895536
   PubMed Web of Science ®Google Scholar
• Chagas MHN, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088–1098. doi:10.1177/0269881114550355
   PubMed Web of Science ®Google Scholar
• Leehey MA, Liu Y, Hart F, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: an Open Label, Dose-Escalation Study. Cannabis Cannabinoid Res. 2020;5(4):326–336. doi:10.1089/can.2019.0068
   PubMedGoogle Scholar
• Peball M, Krismer F, Knaus H, et al. Non‐Motor Symptoms in Parkinson’s Disease are Reduced by Nabilone. Ann. Neurol. 2020;88(4):712–722. doi:10.1002/ana.25864
   PubMed Web of Science ®Google Scholar
• Falco-Walter J. Epilepsy-Definition, Classification, Pathophysiology, and Epidemiology. Semin Neurol. 2020;40(6):617–623. doi:10.1055/s-0040-1718719
   PubMedGoogle Scholar
• Clement AB, Hawkins EG, Lichtman AH, Cravatt BF. Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase. J Neurosci. 2003;23(9):3916–3923. doi:10.1523/JNEUROSCI.23-09-03916.2003
   PubMed Web of Science ®Google Scholar
• Marsicano G, Goodenough S, Monory K, et al. CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity. Science. 2003;302(5642):84–88. doi:10.1126/science.1088208
   PubMed Web of Science ®Google Scholar
• Jones NA, Hill AJ, Smith I, et al. Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo. J Pharmacol Exp Ther. 2010;332(2):569–577. doi:10.1124/jpet.109.159145
   PubMed Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long‐term cannabidiol treatment in patients with Dravet syndrome: an open‐label extension trial. Epilepsia. 2019;60(2):294–302. doi:10.1111/epi.14628
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204–e1211. doi:10.1212/WNL.0000000000005254
   PubMed Web of Science ®Google Scholar
• Gaston TE, Szaflarski M, Hansen B, Bebin EM, Szaflarski JP. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy. Epilepsy Behav. 2019;95:10–17. doi:10.1016/j.yebeh.2019.03.035
   PubMed Web of Science ®Google Scholar
• Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results. Epilepsy Res. 2019;154:13–20. doi:10.1016/j.eplepsyres.2019.03.015
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Gupta JK. Enlightening Pharmacological Mechanisms of Cannabidiol in Epilepsy: a Comprehensive Review on their Neuroprotective Potential. Ind J Pharm Edu Res. 2023;58(1):15–20. doi:10.5530/ijper.58.1.2
   Google Scholar
• Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi:10.1177/1352458520970841
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636. doi:10.1016/S0140-6736(18)30481-1
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex ®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS. Eur J Neurol. 2011;18(9):1122–1131. doi:10.1111/j.1468-1331.2010.03328.x
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis: cannabis-based medicine in spasticity by multiple sclerosis. Eur J Neurol. 2007;14(3):290–296. doi:10.1111/j.1468-1331.2006.01639.x
   PubMed Web of Science ®Google Scholar
• Markovà J, Essner U, Akmaz B, et al. Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129(2):119–128. doi:10.1080/00207454.2018.1481066
   PubMed Web of Science ®Google Scholar
• University of California, Davis. Cannabis for Spasticity in Multiple Sclerosis: a Placebo-Controlled Study (Clinical Trial Registration No. NCT00682929); 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT00682929. Accessed May 10, 2024.
   Google Scholar
• Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, on behalf of the MUSEC Research Group. MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125–1132. doi:10.1136/jnnp-2012-302468
   PubMed Web of Science ®Google Scholar
• Rudroff T Medical Marijuana and its Effects on Motor Function in People with Multiple Sclerosis: an Observational Case-Control Study (Clinical Trial Registration No. NCT02898974); 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02898974. Accessed May 10, 2024.
   Google Scholar
• Walczyńska-Dragon K, Kurek-Górecka A, Niemczyk W, et al. Cannabidiol Intervention for Muscular Tension, Pain, and Sleep Bruxism Intensity—A Randomized, Double-Blind Clinical Trial. JCM. 2024;13(5):1417. doi:10.3390/jcm13051417
   Google Scholar
• Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opinion Neurol. 2019;32(5):771–776. doi:10.1097/WCO.0000000000000730
   PubMed Web of Science ®Google Scholar
• Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6(1):171. doi:10.4103/2152-7806.169561
   PubMedGoogle Scholar
• Liu J, Wang F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: cellular Mechanisms and Therapeutic Implications. Front Immunol. 2017;8:1005. doi:10.3389/fimmu.2017.01005
   PubMed Web of Science ®Google Scholar
• Batra G, Jain M, Singh R, et al. Novel therapeutic targets for amyotrophic lateral sclerosis. Indian J Pharmacol. 2019;51(6):418. doi:10.4103/ijp.IJP_823_19
   PubMed Web of Science ®Google Scholar
• Riva N, Mora G, Sorarù G, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, Phase 2 trial. Lancet Neurol. 2019;18(2):155–164. doi:10.1016/S1474-4422(18)30406-X
   PubMed Web of Science ®Google Scholar
• Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg. 2010;81(10):1135–1140. doi:10.1136/jnnp.2009.200642
   PubMed Web of Science ®Google Scholar
• Petrie GN, Nastase AS, Aukema RJ, Hill MN. Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology. 2021;195:108626. doi:10.1016/j.neuropharm.2021.108626
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600):1706–1713. doi:10.1016/S0140-6736(07)61721-8
   PubMed Web of Science ®Google Scholar
• Moreira FA, Wotjak CT. Cannabinoids and Anxiety. In: Stein MB, Steckler T, editors. Behavioral Neurobiology of Anxiety and Its Treatment. Vol 2. Current Topics in Behavioral Neurosciences. Berlin Heidelberg: Springer; 2009:429–450. doi:10.1007/7854_2009_16
   Google Scholar
• Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA. Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology. 2017;234(14):2207–2217. doi:10.1007/s00213-017-4626-5
   PubMed Web of Science ®Google Scholar
• Todd SM, Arnold JC. Neural correlates of interactions between cannabidiol and Δ 9 -tetrahydrocannabinol in mice: implications for medical cannabis: THC and CBD interactions. Br. J. Pharmacol. 2016;173(1):53–65. doi:10.1111/bph.13333
   PubMed Web of Science ®Google Scholar
• Rubino T, Sala M, Viganò D, et al. Cellular Mechanisms Underlying the Anxiolytic Effect of Low Doses of Peripheral Δ9-Tetrahydrocannabinol in Rats. Neuropsychopharmacol. 2007;32(9):2036–2045. doi:10.1038/sj.npp.1301330
   PubMed Web of Science ®Google Scholar
• Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT1A receptors are involved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur. J. Pharmacol. 2007;555(2–3):156–163. doi:10.1016/j.ejphar.2006.10.038
   PubMed Web of Science ®Google Scholar
• Beletsky A, Liu C, Lochte B, Samuel N, Grant I. Cannabis and Anxiety: a Critical Review. Med Cannabis Cannabinoids. 2024;7(1):19–30. doi:10.1159/000534855
   PubMedGoogle Scholar
• Schmidt ME, Liebowitz MR, Stein MB, et al. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacol. 2021;46(5):1004–1010. doi:10.1038/s41386-020-00888-1
   PubMed Web of Science ®Google Scholar
• Keith JM, Jones WM, Tichenor M, et al. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. ACS Med Chem Lett. 2015;6(12):1204–1208. doi:10.1021/acsmedchemlett.5b00353
   PubMed Web of Science ®Google Scholar
• Ahmed M, Tyndale RF, Rubin-Kahana DS, et al. Investigating Fatty Acid Amide Hydrolase Levels in Social Anxiety Disorder: a Positron Emission Tomography (PET) Study Using [C-11]CURB. Biol. Psychiatry. 2020;87(9):S299. doi:10.1016/j.biopsych.2020.02.770
   Web of Science ®Google Scholar
• Buxton OM, Broussard JL, Zahl AK, Hall M. Effects of Sleep Deficiency on Hormones, Cytokines, and Metabolism. In: Redline S, Berger NA editors. Impact of Sleep and Sleep Disturbances on Obesity and Cancer. Springer New York; 2014:25–50. doi:10.1007/978-1-4614-9527-7_2
   Google Scholar
• Murawski B, Wade L, Plotnikoff RC, Lubans DR, Duncan MJ. A systematic review and meta-analysis of cognitive and behavioral interventions to improve sleep health in adults without sleep disorders. Sleep Med Rev. 2018;40:160–169. doi:10.1016/j.smrv.2017.12.003
   PubMed Web of Science ®Google Scholar
• Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of Healthy Sleep Duration among Adults — United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(6):137–141. doi:10.15585/mmwr.mm6506a1
   PubMed Web of Science ®Google Scholar
• Murillo-Rodríguez E. The role of the CB1 receptor in the regulation of sleep. Prog Neuro Psychopharmacol Biol Psychiatry. 2008;32(6):1420–1427. doi:10.1016/j.pnpbp.2008.04.008
   PubMed Web of Science ®Google Scholar
• Maejima T, Masseck OA, Mark MD, Herlitze S. Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels. Front Integr Neurosci. 2013;7. doi:10.3389/fnint.2013.00040
   PubMedGoogle Scholar
• Kaul M, Zee PC, Sahni AS. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. Neurotherapeutics. 2021;18(1):217–227. doi:10.1007/s13311-021-01013-w
   PubMed Web of Science ®Google Scholar
• Marzo VD, Bifulco M, Petrocellis LD. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771–784. doi:10.1038/nrd1495
   PubMed Web of Science ®Google Scholar
• Hanlon EC, Tasali E, Leproult R, et al. Sleep Restriction Enhances the Daily Rhythm of Circulating Levels of Endocannabinoid 2-Arachidonoylglycerol. Sleep. 2016;39(3):653–664. doi:10.5665/sleep.5546
   PubMed Web of Science ®Google Scholar
• Suraev AS, Marshall NS, Vandrey R, et al. Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Med Rev. 2020;53:101339. doi:10.1016/j.smrv.2020.101339
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Cortes-Briones J, Creatura G, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35–45. doi:10.1016/S2215-0366(18)30427-9
   PubMed Web of Science ®Google Scholar
• Chagas MHN, Crippa JAS, Zuardi AW, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013;27(3):312–316. doi:10.1177/0269881112474524
   PubMed Web of Science ®Google Scholar
• Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology. 1977;55(3):263–265. doi:10.1007/BF00497858
   PubMed Web of Science ®Google Scholar
• Saleska JL, Bryant C, Kolobaric A, et al. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: a Double-Blinded, Randomized Controlled Trial. J Am Nutrition Assoc. 2024;43(1):1–11. doi:10.1080/27697061.2023.2203221
   PubMed Web of Science ®Google Scholar
• Bidwell L, Sznitman S, Martin-Willett R, Hitchcock L. Daily associations with cannabis use and sleep quality in anxious cannabis users. Behav. Sleep Med. 2024;22(2):150–167. doi:10.1080/15402002.2023.2217969
   PubMed Web of Science ®Google Scholar
• Fujimori M, Himwich HE. Δ9-Tetrahydrocannabinol and the sleep-wakefulness cycle in rabbits. Physiol Behav. 1973;11(3):291–295. doi:10.1016/0031-9384(73)90003-6
   PubMed Web of Science ®Google Scholar
• Wallach MB, Gershon S. The effects of Δ8-THC on the EEG, reticular multiple unit activity and sleep of cats. Eur. J. Pharmacol. 1973;24(2):172–178. doi:10.1016/0014-2999(73)90068-X
   PubMed Web of Science ®Google Scholar
• Barratt ES, Adams PM. Chronic marijuana usage and sleep-wakefulness cycles in cats. Biol Psychiatry. 1973;6(3):207–214.
   PubMed Web of Science ®Google Scholar
• Pacek LR, Herrmann ES, Smith MT, Vandrey R. Sleep continuity, architecture and quality among treatment-seeking cannabis users: an in-home, unattended polysomnographic study. Exp. Clin. Psychopharmacol. 2017;25(4):295–302. doi:10.1037/pha0000126
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Δ-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults. J Clin Psychopharmacol. 2004;24(3):305–313. doi:10.1097/01.jcp.0000125688.05091.8f
   PubMed Web of Science ®Google Scholar
• Lavender I, McGregor IS, Suraev A, Grunstein RR. Cannabinoids, Insomnia, and Other Sleep Disorders. Chest. 2022;162(2):452–465. doi:10.1016/j.chest.2022.04.151
   PubMed Web of Science ®Google Scholar
• Cherkasova V, Wang B, Gerasymchuk M, Fiselier A, Kovalchuk O, Kovalchuk I. Use of Cannabis and Cannabinoids for Treatment of Cancer. Cancers. 2022;14(20):5142. doi:10.3390/cancers14205142
   PubMed Web of Science ®Google Scholar
• Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA a Cancer J Clinicians. 2024;74(1):12–49. doi:10.3322/caac.21820
   PubMed Web of Science ®Google Scholar
• Rahman T. Erratum to Cancer statistics, 2024. CA a Cancer J Clinicians. 2024;74(2):203. doi:10.3322/caac.21830
   PubMed Web of Science ®Google Scholar
• Debela DT, Muzazu SG, Heraro KD, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Medicine. 2021:9. doi:10.1177/20503121211034366
   Web of Science ®Google Scholar
• Chakraborty S, Rahman T. The difficulties in cancer treatment. Ecancermedicalscience. 2012;6(16). doi:10.3332/ecancer.2012.ed16
   PubMedGoogle Scholar
• Majeed H, Gupta V. Adverse Effects of Radiation Therapy StatPearls. StatPearls Publishing LLC.; 2023.
   Google Scholar
• Strzelecka K, Piotrowska U, Sobczak M, Oledzka E. The Advancement of Biodegradable Polyesters as Delivery Systems for Camptothecin and Its Analogues—A Status Report. IJMS. 2023;24(2):1053. doi:10.3390/ijms24021053
   Google Scholar
• Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA. 2003;100(3):776–781. doi:10.1073/pnas.0334858100
   PubMed Web of Science ®Google Scholar
• Pyszniak M, Tabarkiewicz J, Łuszczki J. Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance. OTT. 2016;9:4323–4336. doi:10.2147/OTT.S106944
   Google Scholar
• Ramer R, Bublitz K, Freimuth N, et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule‐1. FASEB j. 2012;26(4):1535–1548. doi:10.1096/fj.11-198184
   PubMed Web of Science ®Google Scholar
• Salazar M, Carracedo A, Salanueva ÍJ, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest. 2009;119(5):1359–1372. doi:10.1172/JCI37948
   PubMed Web of Science ®Google Scholar
• Donadelli M, Dando I, Zaniboni T, et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011;2(4):e152–e152. doi:10.1038/cddis.2011.36
   PubMedGoogle Scholar
• Tubaro A, Giangaspero A, Sosa S, et al. Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins. Fitoterapia. 2010;81(7):816–819. doi:10.1016/j.fitote.2010.04.009
   PubMed Web of Science ®Google Scholar
• Anil SM, Peeri H, Koltai H. Medical Cannabis Activity Against Inflammation: active Compounds and Modes of Action. Front Pharmacol. 2022;13:908198. doi:10.3389/fphar.2022.908198
   PubMed Web of Science ®Google Scholar
• Winkler K, Ramer R, Dithmer S, Ivanov I, Merkord J, Hinz B. Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells. Oncotarget. 2016;7(12):15047–15064. doi:10.18632/oncotarget.7592
   PubMedGoogle Scholar
• Buchalska B, Kamińska K, Owe-Larsson M, Cudnoch-Jędrzejewska A. Cannabinoids in the treatment of glioblastoma. Pharmacol Rep. 2024;8:850. doi:10.1007/s43440-024-00580-x
   Google Scholar
• Dasram MH, Naidoo P, Walker RB, Khamanga SM. Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy. IJMS. 2024;25(3):1371. doi:10.3390/ijms25031371
   Google Scholar
• Cretu B, Zamfir A, Bucurica S, et al. Role of Cannabinoids in Oral Cancer. IJMS. 2024;25(2):969. doi:10.3390/ijms25020969
   Google Scholar
• Heider CG, Itenberg SA, Rao J, Ma H, Wu X. Mechanisms of Cannabidiol (CBD) in Cancer Treatment: a Review. Biology. 2022;11(6):817. doi:10.3390/biology11060817
   PubMedGoogle Scholar
• Abrams DI. The therapeutic effects of Cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. Eur J Internal Med. 2018;49:7–11. doi:10.1016/j.ejim.2018.01.003
   PubMed Web of Science ®Google Scholar
• Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda, Board on Population Health and Public Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press; 2017:24625. doi:10.17226/24625
   Google Scholar
• Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: a North Central Cancer Treatment Group Study. JCO. 2002;20(2):567–573. doi:10.1200/JCO.2002.20.2.567
   PubMed Web of Science ®Google Scholar
• Seymour-Jackson E, Laird BJA, Sayers J, Fallon M, Solheim TS, Skipworth R. Cannabinoids in the treatment of cancer anorexia and cachexia: where have we been, where are we going? Asia PacJ Oncol Nurs. 2023;10:100292. doi:10.1016/j.apjon.2023.100292
   PubMed Web of Science ®Google Scholar
• Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: new Insights From Old Molecules. Front Pharmacol. 2018;9:1259. doi:10.3389/fphar.2018.01259
   PubMed Web of Science ®Google Scholar
• Colombo E, Coppini DA, Polito L, et al. Cannabidiol as Self-Assembly Inducer for Anticancer Drug-Based Nanoparticles. Molecules. 2022;28(1):112. doi:10.3390/molecules28010112
   PubMed Web of Science ®Google Scholar
• Baswan SM, Klosner AE, Glynn K, et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. CCID. 2020;13:927–942. doi:10.2147/CCID.S286411
   Google Scholar
• Sheriff T, Lin MJ, Dubin D, Khorasani H. The potential role of cannabinoids in dermatology. J Dermatological Treat. 2020;31(8):839–845. doi:10.1080/09546634.2019.1675854
   PubMed Web of Science ®Google Scholar
• Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatological Sci. 2005;38(3):177–188. doi:10.1016/j.jdermsci.2005.01.007
   PubMed Web of Science ®Google Scholar
• Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem. Pharmacol. 2018;157:122–133. doi:10.1016/j.bcp.2018.08.022
   PubMed Web of Science ®Google Scholar
• Denda M, Tsutsumi M, Goto M, Ikeyama K, Denda S. Topical Application of TRPA1 Agonists and Brief Cold Exposure Accelerate Skin Permeability Barrier Recovery. J Invest Dermatol. 2010;130(7):1942–1945. doi:10.1038/jid.2010.32
   PubMed Web of Science ®Google Scholar
• Denda M, Tsutsumi M, Denda S. Topical application of TRPM8 agonists accelerates skin permeability barrier recovery and reduces epidermal proliferation induced by barrier insult: role of cold-sensitive TRP receptors in epidermal permeability barrier homoeostasis: TRPM8 agonists accelerate barrier recovery. Experimental Dermatol. 2010;19(9):791–795. doi:10.1111/j.1600-0625.2010.01154.x
   PubMed Web of Science ®Google Scholar
• Soliman E, Henderson KL, Danell AS, Van Dross R. Arachidonoyl‐ethanolamide activates endoplasmic reticulum stress‐apoptosis in tumorigenic keratinocytes: role of cyclooxygenase‐2 and novel J‐series prostamides. Mol, Carcinog. 2016;55(2):117–130. doi:10.1002/mc.22257
   PubMed Web of Science ®Google Scholar
• Soliman E, Van Dross R. Anandamide-induced endoplasmic reticulum stress and apoptosis are mediated by oxidative stress in non-melanoma skin cancer: receptor-independent endocannabinoid signaling. Mol, Carcinog. 2016;55(11):1807–1821. doi:10.1002/mc.22429
   PubMed Web of Science ®Google Scholar
• Ständer S, Reinhardt HW, Luger TA. Topische Cannabinoidagonisten: eine effektive, neue Möglichkeit zur Behandlung von chronischem Pruritus. Hautarzt. 2006;57(9):801–807. doi:10.1007/s00105-006-1180-1
   PubMed Web of Science ®Google Scholar
• Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatological Sci. 2007;45(2):87–92. doi:10.1016/j.jdermsci.2006.10.009
   PubMed Web of Science ®Google Scholar
• Carbone A, Siu A, Patel R. Pediatric Atopic Dermatitis: a Review of the Medical Management. Ann Pharmacother. 2010;44(9):1448–1458. doi:10.1345/aph.1P098
   PubMed Web of Science ®Google Scholar
• Soliman E, Ladin D, Van Dross R. Cannabinoids as Therapeutics for Non-Melanoma and Melanoma Skin Cancer. J Dermatol Clin Res. 2016;4(2):1069.
   Google Scholar
• Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Experimental Dermatol. 2009;18(8):669–679. doi:10.1111/j.1600-0625.2009.00923.x
   PubMed Web of Science ®Google Scholar
• Ferreira I, Lopes CM, Amaral MH. Treatment Advances for Acne Vulgaris: the Scientific Role of Cannabinoids. Cosmetics. 2024;11(1):22. doi:10.3390/cosmetics11010022
   Google Scholar
• Lapteva M, Faro Barros J, Kalia YN. Cutaneous Delivery and Biodistribution of Cannabidiol in Human Skin after Topical Application of Colloidal Formulations. Pharmaceutics. 2024;16(2):202. doi:10.3390/pharmaceutics16020202
   PubMed Web of Science ®Google Scholar
• Parikh AC, Jeffery CS, Sandhu Z, Brownlee BP, Queimado L, Mims MM. The effect of cannabinoids on wound healing: a review. Health Sci Rep. 2024;7(2):e1908. doi:10.1002/hsr2.1908
   PubMedGoogle Scholar
• Smith G, Satino J. Hair Regrowth with Cannabidiol (CBD)-rich Hemp Extract - A Case Series. Cannabis. 2021;4(1):53–59. doi:10.26828/cannabis/2021.01.003
   PubMedGoogle Scholar
• Maayah ZH, Takahara S, Ferdaoussi M, Dyck JRB. The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation. Mol Basis Dis. 2020;1866(7):165771. doi:10.1016/j.bbadis.2020.165771
   PubMed Web of Science ®Google Scholar
• Balić A, Vlašić D, Žužul K, Marinović B, Bukvić Mokos Z. Omega-3 Versus Omega-6 Polyunsaturated Fatty Acids in the Prevention and Treatment of Inflammatory Skin Diseases. IJMS. 2020;21(3):741. doi:10.3390/ijms21030741
   Google Scholar
• Moore EM, Wagner C, Komarnytsky S. The Enigma of Bioactivity and Toxicity of Botanical Oils for Skin Care. Front Pharmacol. 2020;11:785. doi:10.3389/fphar.2020.00785
   PubMed Web of Science ®Google Scholar
• Pei L, Luo Y, Gu X, Wang J. Formation, Stability and Properties of Hemp Seed Oil Emulsions for Application in the Cosmetics Industry. Tenside Surfactants Detergents. 2020;57(6):451–459. doi:10.3139/113.110712
   Web of Science ®Google Scholar
• Metwally S, Ura DP, Krysiak ZJ, Kaniuk L, Szewczyk PK, Stachewicz U. Electrospun PCL Patches with Controlled Fiber Morphology and Mechanical Performance for Skin Moisturization via Long-Term Release of Hemp Oil for Atopic Dermatitis. Membranes. 2020;11(1):26. doi:10.3390/membranes11010026
   PubMed Web of Science ®Google Scholar
• Mnekin L, Ripoll L. Topical Use of Cannabis sativa L. Biochemicals. Cosmetics. 2021;8(3):85. doi:10.3390/cosmetics8030085
   Google Scholar
• Anand U, Pacchetti B, Anand P, Sodergren MH. Cannabis-based medicines and pain: a review of potential synergistic and entourage effects. Pain Management. 2021;11(4):395–403. doi:10.2217/pmt-2020-0110
   PubMed Web of Science ®Google Scholar
• Nevozhay D, Kańska U, Budzyńska R, Boratyński J. Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases. Postepy higieny medycyny doswiadczalnej. 2007;61:350–360.
   Google Scholar
• Allen TM, Cullis PR. Drug Delivery Systems: entering the Mainstream. Science. 2004;303(5665):1818–1822. doi:10.1126/science.1095833
   PubMed Web of Science ®Google Scholar
• Zoltowska K, Sobczak M, Oledzka E. Polyurethanes in pharmacy — current state and perspectives of the development. Polimery. 2014;59(10):689–698. doi:10.14314/polimery.2014.689
   Web of Science ®Google Scholar
• Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci, C Polym Symp. 1975;51(1):135–153. doi:10.1002/polc.5070510111
   Google Scholar
• Elvira C, Gallardo A, Roman J, Cifuentes A. Covalent Polymer-Drug Conjugates. Molecules. 2005;10(1):114–125. doi:10.3390/10010114
   PubMed Web of Science ®Google Scholar
• Larson N, Ghandehari H. Polymeric Conjugates for Drug Delivery. Chem Mater. 2012;24(5):840–853. doi:10.1021/cm2031569
   PubMed Web of Science ®Google Scholar
• Negut I, Bita B. Polymeric Micellar Systems—A Special Emphasis on “Smart” Drug Delivery. Pharmaceutics. 2023;15(3):976. doi:10.3390/pharmaceutics15030976
   PubMed Web of Science ®Google Scholar
• Perumal S, Atchudan R, Lee W. A Review of Polymeric Micelles and Their Applications. Polymers. 2022;14(12):2510. doi:10.3390/polym14122510
   PubMed Web of Science ®Google Scholar
• Kaur J, Gulati M, Jha NK, et al. Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation. Drug Discovery Today. 2022;27(5):1495–1512. doi:10.1016/j.drudis.2022.02.005
   PubMed Web of Science ®Google Scholar
• Jung A. Nanoparticles in medical applications - a direction of the future? Pediatr Med Rodz. 2014;10(2):104–110. doi:10.15557/PiMR.2014.0015
   Google Scholar
• Mohanraj VJ, Chen Y. Nanoparticles - A review. Trop J Pharm Res. 2007;5(1):561–573. doi:10.4314/tjpr.v5i1.14634
   Google Scholar
• Budnicka M, Gadomska-Gajadhur A, Ruskowski P, Synoradzki L. Biodegradable polymers for the treatment of tuberculosis Part I. Epidemiology, therapy and treatment methods. Polimery. 2017;62(10):711–719. doi:10.14314/polimery.2017.711
   Web of Science ®Google Scholar
• Niemirowicz K, Car H. Nanonośniki jako nowoczesne transportery w kontrolowanym dostarczaniu leków. CHEMIK. 2012;66(8):868–881.
   Google Scholar
• Tiwari G, Tiwari R, Bannerjee S, et al. Drug delivery systems: an updated review. Int J Pharma Investig. 2012;2(1):2. doi:10.4103/2230-973X.96920
   PubMedGoogle Scholar
• Bajracharya R, Song JG, Patil BR, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Delivery. 2022;29(1):1959–1970. doi:10.1080/10717544.2022.2089296
   PubMed Web of Science ®Google Scholar
• Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977;252(11):3578–3581. doi:10.1016/S0021-9258(17)40291-2
   PubMed Web of Science ®Google Scholar
• Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977;252(11):3582–3586. doi:10.1016/S0021-9258(17)40292-4
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Nagasaki Y. PEGylation Technology in Nanomedicine. In: Kunugi S, Yamaoka T, editors. Polymers in Nanomedicine. Vol 247. Advances in Polymer Science. Berlin Heidelberg: Springer; 2011:115–140. doi:10.1007/12_2011_154
   Google Scholar
• Wang N, Wang T, Li T, Deng Y. Modulation of the physicochemical state of interior agents to prepare controlled release liposomes. Colloids Surf. B. 2009;69(2):232–238. doi:10.1016/j.colsurfb.2008.11.033
   PubMed Web of Science ®Google Scholar
• Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur. J. Pharm. Biopharm. 2012;81(2):265–272. doi:10.1016/j.ejpb.2012.02.009
   PubMed Web of Science ®Google Scholar
• Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022;27(4):1372. doi:10.3390/molecules27041372
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. IJN. 2015;10(1):975–999. doi:10.2147/IJN.S68861
   Google Scholar
• Sarecka-Hujar B, Jankowski A, Wysocka J. Liposomy-postać modyfikująca transport substancji aktywnych przez skórę Część 2. Zastosowanie w transporcie leków o działaniu ogólnoustrojowym. Ann Acad Med Silesiensis. 2011;65(4):45–50.
   Google Scholar
• Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394. doi:10.1016/j.heliyon.2022.e09394
   PubMed Web of Science ®Google Scholar
• Goik U, Załęska-Żyłka I, Pietrzycka A. Liposomes as carriers for the delivery of active substances to the skin. Eng Biomaterials. 2015;18(130):27–39.
   Google Scholar
• Pasarin D, Ghizdareanu AI, Enascuta CE, et al. Coating Materials to Increase the Stability of Liposomes. Polymers. 2023;15(3):782. doi:10.3390/polym15030782
   PubMed Web of Science ®Google Scholar
• Jerbic IS. Biodegradable synthetic polymers and their application in advanced drug delivery systems (DDS). J Chem Eng Process Technol. 2018;1(1):1–9. doi:10.4172/2157-7048-C1-011
   Google Scholar
• Doppalapudi S, Jain A, Khan W, Domb AJ. Biodegradable polymers-an overview. Polym Adv Technol. 2014;25(5):427–435. doi:10.1002/pat.3305
   Web of Science ®Google Scholar
• Prasher P, Sharma M, Mehta M, et al. Current-status and applications of polysaccharides in drug delivery systems. Colloid Interface Sci. Commun. 2021;42:100418. doi:10.1016/j.colcom.2021.100418
   Web of Science ®Google Scholar
• Chanthathamrongsiri N, Petchsomrit A, Leelakanok N, Siranonthana N, Sirirak T. The comparison of the properties of nanocellulose isolated from colonial and solitary marine tunicates. Heliyon. 2021;7(8):e07819. doi:10.1016/j.heliyon.2021.e07819
   PubMed Web of Science ®Google Scholar
• Ioelovich M. Cellulose as a nanostructured polymer: a short review. BioRes. 2008;3(4):1403–1418. doi:10.15376/biores.3.4.Ioelovich
   Web of Science ®Google Scholar
• Klemm D, Cranston ED, Fischer D, et al. Nanocellulose as a natural source for groundbreaking applications in materials science: today’s state. Mater Today. 2018;21(7):720–748. doi:10.1016/j.mattod.2018.02.001
   Web of Science ®Google Scholar
• Seddiqi H, Oliaei E, Honarkar H, et al. Cellulose and its derivatives: towards biomedical applications. Cellulose. 2021;28(4):1893–1931. doi:10.1007/s10570-020-03674-w
   Web of Science ®Google Scholar
• Ahmad Raus R, Wan Nawawi WMF, Nasaruddin RR. Alginate and alginate composites for biomedical applications. Asian J. Pharm. Sci. 2021;16(3):280–306. doi:10.1016/j.ajps.2020.10.001
   PubMed Web of Science ®Google Scholar
• Szekalska M, Puciłowska A, Szymańska E, Ciosek P, Winnicka K. Alginate: current Use and Future Perspectives in Pharmaceutical and Biomedical Applications. Int J Polym Sci. 2016;2016:1–17. doi:10.1155/2016/7697031
   Web of Science ®Google Scholar
• Fu S, Thacker A, Sperger DM, et al. Relevance of Rheological Properties of Sodium Alginate in Solution to Calcium Alginate Gel Properties. AAPS Pharm Sci Tech. 2011;12(2):453–460. doi:10.1208/s12249-011-9587-0
   PubMed Web of Science ®Google Scholar
• Otterlei M, Østgaard K, Skjåk-Bræk G, Smidsrød O, Soon-Shiong P, Espevik T. Induction of Cytokine Production from Human Monocytes Stimulated with Alginate. J Immunother. 1991;10(4):286–291. doi:10.1097/00002371-199108000-00007
   PubMed Web of Science ®Google Scholar
• Thomas S. Alginate dressings in surgery and wound management: part 2. J Wound Care. 2000;9(3):115–119. doi:10.12968/jowc.2000.9.3.25959
   PubMedGoogle Scholar
• Venkatesan J, Bhatnagar I, Manivasagan P, Kang KH, Kim SK. Alginate composites for bone tissue engineering: a review. Int J Biol Macromol. 2015;72:269–281. doi:10.1016/j.ijbiomac.2014.07.008
   PubMed Web of Science ®Google Scholar
• Sun J, Tan H. Alginate-Based Biomaterials for Regenerative Medicine Applications. Materials. 2013;6(4):1285–1309. doi:10.3390/ma6041285
   PubMed Web of Science ®Google Scholar
• Li J, Cai C, Li J, et al. Chitosan-Based Nanomaterials for Drug Delivery. Molecules. 2018;23(10):2661. doi:10.3390/molecules23102661
   PubMed Web of Science ®Google Scholar
• Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Delivery Rev. 2010;62(1):3–11. doi:10.1016/j.addr.2009.09.004
   PubMed Web of Science ®Google Scholar
• Frank LA, Onzi GR, Morawski AS, Pohlmann AR, Guterres SS, Contri RV. Chitosan as a coating material for nanoparticles intended for biomedical applications. React Funct Polym. 2020;147:104459. doi:10.1016/j.reactfunctpolym.2019.104459
   Web of Science ®Google Scholar
• Ali A, Ahmed S. A review on chitosan and its nanocomposites in drug delivery. Int J Biol Macromol. 2018;109:273–286. doi:10.1016/j.ijbiomac.2017.12.078
   PubMed Web of Science ®Google Scholar
• Ways M, Lau T, Khutoryanskiy W. Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers. 2018;10(3):267. doi:10.3390/polym10030267
   PubMed Web of Science ®Google Scholar
• Bhatia S. Natural Polymers vs Synthetic Polymer. In: Natural Polymer Drug Delivery Systems. Springer International Publishing; 2016:95–118. doi:10.1007/978-3-319-41129-3_3
   Google Scholar
• Piskin E. Biodegradable polymers as biomaterials. J biomater sci Poly ed. 1995;6(9):775–795. doi:10.1163/156856295X00175
   PubMed Web of Science ®Google Scholar
• Chandra R. Biodegradable polymers. Prog Polym Sci. 1998;23(7):1273–1335. doi:10.1016/S0079-6700(97)00039-7
   Web of Science ®Google Scholar
• Duda A, Penczek S. Polylactide [poly(lactic acid)]: synthesis, properties and applications. p. 2003;48(1):16–27.
   Google Scholar
• Luo F, Fortenberry A, Ren J, Qiang Z. Recent Progress in Enhancing Poly(Lactic Acid) Stereocomplex Formation for Material Property Improvement. Front Chem. 2020;8:688. doi:10.3389/fchem.2020.00688
   PubMed Web of Science ®Google Scholar
• Capuana E, Lopresti F, Ceraulo M, La Carrubba V. Poly-l-Lactic Acid (PLLA)-Based Biomaterials for Regenerative Medicine: a Review on Processing and Applications. Polymers. 2022;14(6):1153. doi:10.3390/polym14061153
   PubMed Web of Science ®Google Scholar
• Casalini T, Rossi F, Castrovinci A, Perale G. A Perspective on Polylactic Acid-Based Polymers Use for Nanoparticles Synthesis and Applications. Front Bioeng Biotechnol. 2019;7:259. doi:10.3389/fbioe.2019.00259
   PubMed Web of Science ®Google Scholar
• Andrzejewska A, Topoliński T. Biodegradable polymers for biomedical applications. Dev Mech Engi. 2015;6(3):5–12.
   Google Scholar
• Ragaert K, De Somer F, Van de Velde S, Degrieck J, Cardon L. Methods for Improved Flexural Mechanical Properties of 3D-Plotted PCL-Based Scaffolds for Heart Valve Tissue Engineering. SV-JME. 2013;59(11):669–676. doi:10.5545/sv-jme.2013.1003
   Google Scholar
• Znajewska Z. Biodegradacja polikaprolaktonu przez grzyby Trichoderma viride. Chem Rev. 2018;1(10):78–81. doi:10.15199/62.2018.10.8
   Google Scholar
• Woodruff MA, Hutmacher DW. The return of a forgotten polymer—Polycaprolactone in the 21st century. Prog Polym Sci. 2010;35(10):1217–1256. doi:10.1016/j.progpolymsci.2010.04.002
   Web of Science ®Google Scholar
• Budak K, Sogut O, Aydemir Sezer U. A review on synthesis and biomedical applications of polyglycolic acid. J Polym Res. 2020;27(8):208. doi:10.1007/s10965-020-02187-1
   Web of Science ®Google Scholar
• Kumar N, Ravikumar MNV, Domb AJ. Biodegradable block copolymers. Adv. Drug Delivery Rev. 2001;53(1):23–44. doi:10.1016/S0169-409X(01)00219-8
   PubMed Web of Science ®Google Scholar
• Surya N, Bhattacharyya S. PLGA-THE SMART POLYMER FOR DRUG DELIVERY. Farm Farmakol. 2021;9(5):334–345. doi:10.19163/2307-9266-2021-9-5-334-345
   Google Scholar
• Machatschek R, Schulz B, Lendlein A. The influence of pH on the molecular degradation mechanism of PLGA. MRS Adv. 2018;3(63):3883–3889. doi:10.1557/adv.2018.602
   Google Scholar
• Chandrasekaran AR, Venugopal J, Sundarrajan S, Ramakrishna S. Fabrication of a nanofibrous scaffold with improved bioactivity for culture of human dermal fibroblasts for skin regeneration. Biomed Mater. 2011;6(1):015001. doi:10.1088/1748-6041/6/1/015001
   PubMed Web of Science ®Google Scholar
• Li F, Li X, He R, Cheng J, Ni Z, Zhao G. Preparation and evaluation of poly(D, L-lactic acid)/poly(L-lactide-co-ε-caprolactone) blends for tunable sirolimus release. Colloids Surf. A. 2020;590:124518. doi:10.1016/j.colsurfa.2020.124518
   Google Scholar
• Sang Q, Li H, Williams G, Wu H, Zhu LM. Core-shell poly(lactide-co-ε-caprolactone)-gelatin fiber scaffolds as pH-sensitive drug delivery systems. J Biomater Appl. 2018;32(8):1105–1118. doi:10.1177/0885328217749962
   PubMed Web of Science ®Google Scholar
• Abu Abed OS, Chaw C, Williams L, Elkordy AA. Lysozyme and DNase I loaded poly (D, L lactide-co-caprolactone) nanocapsules as an oral delivery system. Sci Rep. 2018;8(1):13158. doi:10.1038/s41598-018-31303-x
   PubMedGoogle Scholar
• Lee SH, Kim BS, Kim SH, et al. Elastic biodegradable poly(glycolide-co-caprolactone) scaffold for tissue engineering. J Biomed Mater Res. 2003;66A(1):29–37. doi:10.1002/jbm.a.10497
   Web of Science ®Google Scholar
• Chen S, Deng C, Zheng W, et al. Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021;13(9):1415. doi:10.3390/pharmaceutics13091415
   PubMed Web of Science ®Google Scholar
• Chevalier MT, Al-Waeel M, Alsharabasy AM, Rebelo AL, Martin-Saldaña S, Pandit A. Therapeutic Polymer-Based Cannabidiol Formulation: tackling Neuroinflammation Associated with Ischemic Events in the Brain. Mol Pharm. 2024;acs.molpharmaceut.3c00244. doi:10.1021/acs.molpharmaceut.3c00244
   PubMedGoogle Scholar
• Fraguas-Sánchez AI, Torres-Suárez AI, Cohen M, et al. PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: in Vitro and In Ovo Assessment. Pharmaceutics. 2020;12(5):439. doi:10.3390/pharmaceutics12050439
   PubMed Web of Science ®Google Scholar
• Muresan P, Woodhams S, Smith F, et al. Evaluation of cannabidiol nanoparticles and nanoemulsion biodistribution in the central nervous system after intrathecal administration for the treatment of pain. Nanomed Nanotechnol Biol Med. 2023;49:102664. doi:10.1016/j.nano.2023.102664
   PubMed Web of Science ®Google Scholar
• Shreiber-Livne I, Sulimani L, Shapira A, Procaccia S, Meiri D, Sosnik A. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) nanoparticles as a platform for the improved oral delivery of cannabidiol. Drug Deliv Transl Res. 2023;13:3192–3203. doi:10.1007/s13346-023-01380-1
   PubMed Web of Science ®Google Scholar
• Monou PK, Mamaligka AM, Tzimtzimis EK, et al. Fabrication and Preliminary In Vitro Evaluation of 3D-Printed Alginate Films with Cannabidiol (CBD) and Cannabigerol (CBG) Nanoparticles for Potential Wound-Healing Applications. Pharmaceutics. 2022;14(8):1637. doi:10.3390/pharmaceutics14081637
   PubMed Web of Science ®Google Scholar
• Hernán Pérez de la Ossa D, Ligresti A, Gil-Alegre ME, et al. Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. J Control Release. 2012;161(3):927–932. doi:10.1016/j.jconrel.2012.05.003
   PubMed Web of Science ®Google Scholar
• Kamali A, Oryan A, Hosseini S, et al. Cannabidiol-loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical-sized bone defects. Mater Sci Eng C. 2019;101:64–75. doi:10.1016/j.msec.2019.03.070
   PubMed Web of Science ®Google Scholar
• Kamali A, Oryan A, Hosseini S, et al. Corrigendum to Cannabidiol-loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical-sized bone defects. Mater Sci Eng C. 2021;126:112179. doi:10.1016/j.msec.2021.112179
   PubMed Web of Science ®Google Scholar
• Hernán Pérez De La Ossa D, Lorente M, Gil-Alegre ME, et al. Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma Multiforme. PLoS One. 2013;8(1):e54795. doi:10.1371/journal.pone.0054795
   PubMed Web of Science ®Google Scholar
• Fraguas-Sánchez AI, Fernández-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Suárez AI. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. Int J Pharm. 2020;574:118916. doi:10.1016/j.ijpharm.2019.118916
   PubMedGoogle Scholar
• David C, De Souza JF, Silva AF, et al. Cannabidiol-loaded microparticles embedded in a porous hydrogel matrix for biomedical applications. J Mater Sci Mater Med. 2024;35(1):14. doi:10.1007/s10856-023-06773-9
   PubMed Web of Science ®Google Scholar
• Toncheva-Moncheva N, Dimitrov E, Grancharov G, Momekova D, Petrov P, Rangelov S. Cinnamyl-Modified Polyglycidol/Poly(ε-Caprolactone) Block Copolymer Nanocarriers for Enhanced Encapsulation and Prolonged Release of Cannabidiol. Pharmaceutics. 2023;15(8):2128. doi:10.3390/pharmaceutics15082128
   PubMed Web of Science ®Google Scholar
• Demisli S, Galani E, Goulielmaki M, et al. Encapsulation of cannabidiol in oil-in-water nanoemulsions and nanoemulsion-filled hydrogels: a structure and biological assessment study. J Colloid Interface Sci. 2023;634:300–313. doi:10.1016/j.jcis.2022.12.036
   PubMed Web of Science ®Google Scholar
• Durán-Lobato M, Muñoz-Rubio I, Holgado MÁ, Álvarez-Fuentes J, Fernández-Arévalo M, Martín-Banderas L. Enhanced Cellular Uptake and Biodistribution of a Synthetic Cannabinoid Loaded in Surface-Modified Poly(lactic-co-glycolic acid) Nanoparticles. J Biomed Nanotechnol. 2014;10(6):1068–1079. doi:10.1166/jbn.2014.1806
   PubMed Web of Science ®Google Scholar
• Durán-Lobato M, Martín-Banderas L, Gonçalves LMD, Fernández-Arévalo M, Almeida AJ. Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids. J Nanopart Res. 2015;17(2):61. doi:10.1007/s11051-015-2875-y
   Web of Science ®Google Scholar
• Berrocoso E, Rey-Brea R, Fernández-Arévalo M, Micó JA, Martín-Banderas L. Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days. Nanomed Nanotechnol Biol Med. 2017;13(8):2623–2632. doi:10.1016/j.nano.2017.07.010
   PubMed Web of Science ®Google Scholar
• Martín-Banderas L, Muñoz-Rubio I, Prados J, et al. In vitro and in vivo evaluation of Δ9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy. Int J Pharm. 2015;487(1–2):205–212. doi:10.1016/j.ijpharm.2015.04.054
   PubMedGoogle Scholar
• Al-Ghananeem AM, Malkawi AH, Crooks PA. Bioavailability of Δ 9 -tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. Drug Dev. Ind. Pharm. 2011;37(3):329–334. doi:10.3109/03639045.2010.513009
   PubMed Web of Science ®Google Scholar
• Román-Vargas Y, Porras-Arguello JD, Blandón-Naranjo L, Pérez-Pérez LD, Benjumea DM. Evaluation of the Analgesic Effect of High-Cannabidiol-Content Cannabis Extracts in Different Pain Models by Using Polymeric Micelles as Vehicles. Molecules. 2023;28(11):4299. doi:10.3390/molecules28114299
   PubMed Web of Science ®Google Scholar
• Porras JD, Román Y, Palacio J, Blandón-Naranjo L, Benjumea D, Pérez LD. Amphiphilic block copolymers bearing fatty acid derivatives as vehicles for THC in the development of analgesic oral formulations. React Funct Polym. 2024;195:105811. doi:10.1016/j.reactfunctpolym.2023.105811
   Web of Science ®Google Scholar
• Villate A, San Nicolas M, Olivares M, Aizpurua-Olaizola O, Usobiaga A. Chitosan-Coated Alginate Microcapsules of a Full-Spectrum Cannabis Extract: characterization, Long-Term Stability and In Vitro Bioaccessibility. Pharmaceutics. 2023;15(3):859. doi:10.3390/pharmaceutics15030859
   PubMed Web of Science ®Google Scholar
• Uziel A, Gelfand A, Amsalem K, et al. Full-Spectrum Cannabis Extract Microdepots Support Controlled Release of Multiple Phytocannabinoids for Extended Therapeutic Effect. ACS Appl Mater Interfaces. 2020;12(21):23707–23716. doi:10.1021/acsami.0c04435
   PubMed Web of Science ®Google Scholar
• Grotenhermen F, Müller-Vahl K. The Therapeutic Potential of Cannabis and Cannabinoids. Dtsch Arztebl Int. 2012;109(29–30):495–501. doi:10.3238/arztebl.2012.0495
   PubMed Web of Science ®Google Scholar
• Weber J, Schley M, Casutt M, et al. Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: results of a Multicenter Survey. Anesthesiology Res Practice. 2009;2009:1–9. doi:10.1155/2009/827290
   Google Scholar